4BIO Capital Portfolio Company Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease

4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity

4BIO Capital Strengthens Advisory Board and Investment Team

Development Bank of Japan invests in 4BIO Capital’s Ventures III fund

4BIO Capital jointly leads $25 million Series A financing of ViaNautis Bio

Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical